Why Israel Is a Major M&A Market
Israel's technology sector generates one of the highest rates of M&A activity per capita in the world. Often called the "Startup Nation," Israel is home to more than 6,000 active startups and has produced a remarkable concentration of globally significant technology companies in cybersecurity, enterprise software, semiconductor design, agritech, medtech, and fintech. US technology giants — including Intel, Google, Microsoft, Apple, Amazon, and Cisco — have made dozens of acquisitions of Israeli companies, and European and Asian strategic buyers have increasingly recognized Israel as a critical source of innovation and engineering talent. This sustained buyer interest, combined with a mature Israeli venture capital ecosystem and an internationally sophisticated legal and financial advisory community, makes Israel a genuinely global M&A market operating under its own distinct legal and regulatory framework.
For foreign buyers, Israel offers compelling acquisition targets but also a set of legal and regulatory considerations that differ meaningfully from what buyers encounter in the US, UK, or Western Europe. Israeli M&A follows broadly US-influenced deal conventions — LOI, exclusivity, due diligence, SPA, representations and warranties, indemnification escrow — but with Israeli-specific overlays in tax law, employment law, intellectual property ownership, government grant restrictions, and securities regulation. A foreign buyer that approaches an Israeli deal assuming it will be identical to a US or UK acquisition is likely to face expensive surprises. The overlays are manageable with proper preparation, but they require Israeli-qualified legal advice from the early stages of the process, not as an afterthought before signing.
The Israeli M&A market has also evolved significantly in its sophistication and deal complexity. Early acquisitions of Israeli companies were often simple share purchases at relatively modest valuations. Today, cross-border Israeli M&A regularly involves complex structures — deferred consideration, milestone payments, earnout provisions tied to technology or revenue targets, equity rollover by founders into the acquirer's parent, and sophisticated representations and warranties insurance products. Israeli investment banks, law firms, and accounting firms advising on these transactions are of international calibre, and foreign buyers should expect negotiations conducted at a high level of commercial and legal sophistication. Preparation is everything: acquirers who arrive at the table having already engaged specialist Israeli counsel and conducted preliminary legal scoping are far better positioned than those who treat Israeli legal due diligence as a routine formality.
The Israeli M&A Process
The Israeli M&A process for private company acquisitions follows a well-established sequence that will be familiar in outline to any international deal practitioner, while containing important Israeli-specific elements at each stage. The process typically begins with an NDA (non-disclosure agreement) — Israeli NDAs are governed by Israeli contract law and its good faith obligations — followed by a letter of intent (LOI) or term sheet. The LOI is typically non-binding on price and terms (except for exclusivity and confidentiality provisions, which are binding), and Israeli courts treat it as an expression of intent rather than a binding commitment — though prolonged LOI negotiations that raise a reasonable expectation of deal completion can create pre-contractual obligations under Israeli good faith law if a party then walks away without justification. Exclusivity periods of 30–60 days are standard.
Due diligence in an Israeli M&A deal covers legal, financial, technical, and IP matters and typically takes 4–8 weeks for a mid-size technology company. Legal due diligence focuses on: corporate records (shareholder agreements, board minutes, option plans); intellectual property (ownership, registrations, freedom to operate, open source compliance); employment law (correctly classified employees vs. contractors; employment agreements; compliance with mandatory Israeli labour law provisions); material contracts (with customers, suppliers, and partners); real estate (office leases); data protection (Israel Privacy Protection Law and GDPR if applicable); and regulatory matters including IIA grants. IP due diligence deserves particular attention in Israeli technology companies because Israeli employment law creates default IP ownership by the employer — but contractors' IP assignments must be expressly documented. Missing or deficient IP assignment agreements are one of the most common Israeli M&A due diligence findings.
Following due diligence, the parties negotiate and execute a share purchase agreement (SPA) or merger agreement. Israeli M&A SPAs are typically drafted in English and are substantively similar to US-style SPAs — representations and warranties, covenants, conditions to closing, indemnification, and escrow arrangements. Israeli legal nuances that often require bespoke drafting include: the interaction between SPA representations and Israeli disclosure obligations; IIA grant assignment provisions; Section 102 option plan treatment; and employment law representations covering severance obligations. Regulatory approvals — particularly IIA clearance and, if applicable, competition authority clearance — are typically conditions precedent to closing. Post-closing, the share transfer must be registered with the Companies Registrar, and various Israeli tax filings and withholding obligations must be addressed.
Deal Structures Under Israeli Law
Share Purchase. The most common structure for acquiring an Israeli private company is a straightforward share purchase: the buyer acquires shares from existing shareholders, and the target company becomes a wholly-owned (or majority-owned) subsidiary of the buyer. This structure is clean from a legal continuity perspective — the company's contracts, licences, and employees remain in place without the need for third-party consents (other than change-of-control provisions in material contracts). For the buyer, the main disadvantage is that it acquires the company's historical liabilities along with its assets. Representations, warranties, and indemnification provisions in the SPA, together with an escrow holdback, address this risk.
Asset Purchase. An asset purchase — acquiring specific assets of an Israeli company rather than its shares — is far less common in Israeli M&A but is used in specific situations, such as acquiring a business division of a larger company or acquiring assets out of insolvency. The key complication is Israeli employment law: when a business is transferred as a going concern (including its employees), Israeli law imposes obligations regarding employee transfer, consent, and continuity of employment terms. Employees cannot simply be dismissed as part of an asset sale; the buyer either takes them on with their existing entitlements or the seller must make the severance payments. Additional complexity arises from the need to individually assign each material contract and licence to the buyer — counterparty consents are often required.
Statutory Merger and Tender Offer. Israeli company law provides for a statutory merger mechanism (mivneh kfiya) that allows two companies to merge with court approval and without requiring individual shareholder consent from each holder — useful for squeezing out small minorities. A statutory merger requires a shareholder vote meeting specified thresholds and court approval, and it takes significantly longer than a share purchase. For TASE-listed Israeli companies, a tender offer (haznaha) is the primary acquisition mechanism, governed by the Securities Law 1968 and the Israel Securities Authority's detailed regulations. A full tender offer for a TASE-listed company triggers specific disclosure, timing, and procedural requirements that differ materially from US tender offer rules, and foreign acquirers should engage Israeli securities counsel at the earliest stages of any TASE-listed target transaction.
Israel Innovation Authority (IIA) Restrictions
One of the most important and sometimes most expensive Israeli M&A-specific issues is the existence of Israel Innovation Authority (IIA) grants in the target company's history. The IIA (formerly the Office of the Chief Scientist, or OCS) provides funding to Israeli technology companies as a grant for approved R&D programs. These grants come with conditions: the technology developed with IIA funding — the "know-how" — cannot be transferred outside Israel, and the company cannot be acquired by a foreign buyer without IIA approval. This is not a matter of disclosure only; without IIA approval, an acquisition of an IIA-grantee company by a foreign buyer may violate the conditions of the grant, exposing both buyer and seller to significant legal and financial consequences.
When IIA approval is required for a foreign acquisition, the buyer must apply to the IIA and, as a condition of approval, typically pay a "know-how fee" to the IIA. This fee is calculated based on the total grants received by the company, with a multiplier that increases depending on where the technology will be developed post-acquisition. If the technology will remain in Israel, the fee is lower (often 3x the grant amount). If the technology will be moved to the buyer's home country, the fee is higher — potentially 6x or more the cumulative grant amount. For companies that have received many millions of dollars in IIA grants over multiple funding programs, this obligation can be a very significant cost that must be factored into deal pricing from the outset. IIA approval timelines (typically 3–6 months) must also be built into deal structuring and financing plans.
Due diligence must identify all IIA grant obligations comprehensively and early. This means reviewing not just current IIA grants but the complete history of government funding received by the company, including grants received under different program names or by predecessor entities that were merged into the target. It is also essential to verify that the IIA's records of the know-how match the technology actually owned by the company — discrepancies can create additional complications. The IIA approval process itself involves submitting a detailed application, a business plan for post-acquisition operations in Israel, and potentially a commitment to maintain a minimum level of R&D activity in Israel. Buyers who treat IIA due diligence as a checkbox rather than a substantive investigation often discover late in a deal that the compliance obligation is larger than anticipated — and by that point, renegotiating price is difficult.
M&A Tax Considerations
Capital Gains and Seller Taxation. For Israeli resident sellers, the gain on sale of shares in an Israeli company is generally subject to Israeli capital gains tax. The applicable rate depends on whether the shares are in a company qualifying under specific tax regimes and the nature of the shareholder (individual or corporate). For non-resident sellers, Israeli capital gains tax may also apply — Israel taxes gains on shares in Israeli companies held by foreign residents — but most of Israel's extensive network of tax treaties (including with the US, UK, Germany, France, and many other countries) provide for exemption or reduced withholding on capital gains for qualifying non-residents. Before structuring a sale, sellers should analyse whether they qualify for treaty relief and, if not, what Israeli tax will be owed on the gain.
Reorganizations and Employee Option Taxation. Section 104 of the Israeli Income Tax Ordinance provides for tax-neutral reorganizations — share-for-share exchanges and certain other restructurings can be effected without immediate capital gains tax recognition, subject to conditions including holding period requirements and pre-approval from the Israeli Tax Authority. These provisions are frequently used in preparatory restructuring before an acquisition or IPO. Of equal importance in most Israeli tech M&A deals is the treatment of employee share options under Section 102. Upon a change of control, unvested options often accelerate, and the tax treatment of the resulting employee gains — capital gains under the Section 102 capital gains track, or income tax if the 24-month trustee holding period has not been met — affects how much of the acquisition consideration is ultimately received by the employee option holders. Buyers should model out the option pool waterfall carefully, taking account of the applicable Section 102 tax treatment.
Withholding Obligations. Foreign acquirers must be aware that Israeli tax law requires the buyer to withhold Israeli tax from payments to non-resident sellers unless the seller obtains a withholding tax exemption certificate from the Israeli Tax Authority. This is an active obligation on the buyer — failure to withhold can make the buyer liable for the seller's unpaid Israeli taxes. Sellers from treaty countries should apply for an exemption or reduced rate certificate in advance of closing. The withholding obligation applies to the gross purchase price, not just the gain, unless a certificate is obtained — which makes it essential for sellers from any country to engage Israeli tax counsel and apply for the necessary certificate well before closing. Experienced Israeli deal counsel for both buyer and seller will manage this process as a routine matter, but it can cause serious problems if left until the last moment.